Beau Nakamoto to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications Beau Nakamoto has written about Antiretroviral Therapy, Highly Active.
Connection Strength
0.540
-
Nakamoto BK, McMurtray A, Davis J, Valcour V, Watters MR, Shiramizu B, Chow DC, Kallianpur K, Shikuma CM. Incident neuropathy in HIV-infected patients on HAART. AIDS Res Hum Retroviruses. 2010 Jul; 26(7):759-65.
Score: 0.334
-
Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, Paul R, Zhang G, Ho E, Hanks N, Nakamoto B, Shiramizu BT, Shikuma CM. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neurovirol. 2014 Dec; 20(6):571-82.
Score: 0.112
-
Premeaux TA, D'Antoni ML, Abdel-Mohsen M, Pillai SK, Kallianpur KJ, Nakamoto BK, Agsalda-Garcia M, Shiramizu B, Shikuma CM, Gissl?n M, Price RW, Valcour V, Ndhlovu LC. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. J Neurovirol. 2019 04; 25(2):150-161.
Score: 0.037
-
Chow DC, Kagihara JM, Zhang G, Souza SA, Hodis HN, Li Y, Mitchell BI, Nakamoto BK, Kallianpur KJ, Keating SM, Norris PJ, Kohorn LB, Ndhlovu LC, Shikuma CM. Non-classical monocytes predict progression of carotid artery bifurcation intima-media thickness in HIV-infected individuals on stable antiretroviral therapy. HIV Clin Trials. 2016 05; 17(3):114-22.
Score: 0.031
-
Tongma C, Shikuma CM, Nakamoto BK, Kallianpur KJ, Umaki TM, Barbour JD, Ndhlovu L, Parikh NI, Chow DC. Albuminuria as a marker of cardiovascular risk in HIV-infected individuals receiving stable antiretroviral therapy. Hawaii J Med Public Health. 2013 Sep; 72(9 Suppl 4):34-8.
Score: 0.026